Beta Drugs's EBIT per Share for the
three
months ended in Mar. 2026 was ₹15.57.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹30.27.
During the past 12 months, the average EBIT per Share Growth Rate of Beta Drugs was -6.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 10.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 24.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 36.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Beta Drugs's EBIT per Share or its related term are showing as below:
NSE:BETA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 10.6 Med: 42.65 Max: 283.5
Current: 10.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Beta Drugs was 283.50% per year. The lowest was 10.60% per year. And the median was 42.65% per year.
NSE:BETA's 3-Year EBIT Growth Rate is ranked better than 54.69% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs NSE:BETA: 10.60
Beta Drugs's EBIT for the
three
months ended in Mar. 2026 was ₹158 Mil.
Beta Drugs (NSE:BETA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Beta Drugs EBIT per Share Related Terms
Beta Drugs EBIT per Share Historical Data
* Premium members only.
The historical data trend for Beta Drugs's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹30.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a EBIT per Share of ₹30.27 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Beta Drugs and its competitors. According to the industry distribution chart, Beta Drugs ranks #367 out of 810 companies in the Drug Manufacturers industry, placing it in the top 45.3%.
Is Beta Drugs' EBIT per Share too high?
Beta Drugs' current EBIT per Share is ₹30.27. Based on the distribution chart, Beta Drugs ranks #367 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #367 out of 810 companies for EBIT per Share. This puts Beta Drugs in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current EBIT per Share is ₹30.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,975.60, compared to a current price of ₹2,366.80 — trading 19.8% above its estimated fair value. The current EBIT per Share is ₹30.27. Beta Drugs' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current EBIT per Share is ₹30.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,366.80 is trading 19.8% above its estimated GF Value™ of ₹1,975.60.
GuruFocus considers Beta Drugs to be Modestly Overvalued.
Key valuation signals for NSE:BETA:
EBIT per Share: ₹30.27
GF Value™: ₹1,975.60 vs. price of ₹2,366.80 (19.8% above fair value)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
91GF Score
Get the complete analysis for NSE:BETA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
